Download PDF
Exp Clin Endocrinol Diabetes 2020; 128(12): 835-844
DOI: 10.1055/a-1120-8277
Review

Pituitary Adenomas with Changing Phenotype: A Systematic Review

Fernando Guerrero-Pérez 
1   Department of Endocrinology, Bellvitge University Hospital, Barcelona, Spain
,
Agustina Pia Marengo
1   Department of Endocrinology, Bellvitge University Hospital, Barcelona, Spain
,
Noemi Vidal
2   Department of Pathology; Bellvitge University Hospital, Barcelona, Spain
,
Carles Villabona
1   Department of Endocrinology, Bellvitge University Hospital, Barcelona, Spain
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose and Methods Phenotype transformation in pituitary adenomas (PA) is a little known and unexpected clinical phenomenon. We describe two illustrative cases and performed a systematic review of cases reported in literature.

Results Case 1: A 24-year-old woman underwent surgery because of Cushing’s disease. A complete tumor resection and hypercortisolism resolution was achieved. Two years later, tumor recurred but clinical and hormonal hypercortisolism were absent. Case 2: A 77-year-old woman underwent surgery due to acromegaly. A complete tumor resection and GH excess remission was achieved. Four years later, tumor recurred but clinical and hormonal acromegaly was ruled out. Search of literature: From 20 patients (including our cases), 75% were female with median age 45 (19) years. Ten patients (50%) had initially functioning PA: 8 switched to NFPA (5 ACTH-secreting PA, 2 prolactinomas and 1 acromegaly) and 2 exchanged to acromegaly from TSH-secreting PA and microprolactinoma. One patient developed a pituitary carcinoma from ACTH-secreting PA. Ten patients (50%) initially had NFPA; 9 developed Cushing’s disease (4 silent corticotroph adenomas, 4 null cell PA and 1 managed conservatively). One patient with silent somatotroph PA changed to acromegaly. Treatments before transformation were surgery (80%), radiotherapy (40%), pharmacological (40%) and in 2 patients switching happened without any treatment. Median follow-up until transformation was 72 months (range 12–276).

Conclusion PA can change from functioning to (NF) non-functioning (vice versa) and even exchange their hormonal expression. Clinicians should be aware and a careful lifelong follow-up is mandatory to detect it.

Key words

pituitary adenoma with switching phenotypes - pituitary adenoma transformation - pituitary adenoma metamorphosis


Publication History

Received: 13 November 2019
Received: 06 February 2020

Accepted: 17 February 2020

Article published online:
14 April 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Melmed S, Kleinberg D. Pituitary masses and tumors. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM Ed Williams Textbook of Endocrinology Elsevier; Philadelphia: 2016: 232-299
    Google Scholar
  • 2 Osamura RY, Grossman A, Korbonits M. et al. Pituitary adenomas. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, Ed WHO Classifications Of Tumors of the Endocrine Organs. WHO Press; Lyon, France: 2017: 14-18
    Google Scholar
  • 3 Katznelson L, Laws ER, Melmed S. et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
    CrossrefPubMedGoogle Scholar
  • 4 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 273-288
    CrossrefPubMedGoogle Scholar
  • 5 Nieman LK, Biller BM, Findling JW. et al. Treatment of Cushingʼs Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831
    CrossrefPubMedGoogle Scholar
  • 6 Watanobe H, Kudo K, Okushima T. et al. A null cell adenoma of the pituitary detected seven years after removal of a prolactinoma. Recurrence or de novo tumourigenesis?. Acta Endocrinol (Copenh) 1991; 125: 700-704
    CrossrefPubMedGoogle Scholar
  • 7 Zoli M, Faustini-Fustini M, Mazzatenta D. et al. ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus 2015; 38: E15
    CrossrefPubMedGoogle Scholar
  • 8 Daems T, Verhelst J, Michotte A. et al. Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 2009; 12: 80-86
    CrossrefPubMedGoogle Scholar
  • 9 Lania AG, Ferrero S, Pivonello R. et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 2010; 95: 13-17
    CrossrefPubMedGoogle Scholar
  • 10 Tan EU, Ho MS, Rajasoorya CR. Metamorphosis of a non-functioning pituitary adenoma to Cushingʼs disease. Pituitary 2000; 3: 117-122
    CrossrefPubMedGoogle Scholar
  • 11 Dessimoz C, Browaeys P, Maeder P. et al. Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma. Front Endocrinol (Lausanne) 2012; 12: 116
    PubMedGoogle Scholar
  • 12 Righi A, Faustini-Fustini M, Morandi L. et al. The changing faces of corticotroph cell adenomas: The role of prohormone convertase 1/3. Endocrine 2017; 56: 286-297
    CrossrefPubMedGoogle Scholar
  • 13 Fang H, Tian R, Wu H. et al. Cushing disease after treatment of nonfunctional pituitary adenoma: A case report and literature review. Medicine (Baltimore) 2015; 94: e2134
    CrossrefPubMedGoogle Scholar
  • 14 Lee EK, Kim JH, Yu HG. Candida albicans endophthalmitis in a patient with a non-functioning pituitary adenoma evolving into Cushingʼs disease: A case report. Med Mycol Case Rep 2014; 16: 37-41
    CrossrefPubMedGoogle Scholar
  • 15 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation elaboration. J Clin Epidemiol 2009; 62: e1-e34
    CrossrefPubMedGoogle Scholar
  • 16 Rotman LE, Vaughan TB, Hackney JR. et al. Long-term survival after transformation of an adrenocorticotropic hormone-secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma. World Neurosurg 2019; 122: 417-423
    CrossrefPubMedGoogle Scholar
  • 17 Glynn N, Agha A. Unexpected clinical course during treatment of a TSH-secreting pituitary adenoma. Endocr Pract 2013; 19: e88-e91
    CrossrefPubMedGoogle Scholar
  • 18 Brown RL, Wollman R, Weiss RE. Transformation of a pituitary macroadenoma into a corticotropin-secreting carcinoma over 16 years. Endocr Pract 2007; 13: 463-471
    CrossrefPubMedGoogle Scholar
  • 19 Salgado LR, Machado MC, Cukiert A. et al. Cushingʼs disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol 2006; 17: 191-199
    CrossrefPubMedGoogle Scholar
  • 20 Dickstein G, Arad E, Shechner C. Late complications in remission from Cushing disease. Recurrence of tumor with reinfarction or transformation into a silent adenoma. Arch Intern Med 1997; 157: 2377-2380
    CrossrefPubMedGoogle Scholar
  • 21 Batisse M, Raverot G, Maqdasy S. et al. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 2013; 31: 190-196
    CrossrefPubMedGoogle Scholar
  • 22 Baldeweg SE, Pollock JR, Powell M. et al. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 2005; 19: 38-42
    CrossrefPubMedGoogle Scholar
  • 23 Melmed S. Mechanisms for pituitary tumorigenesis: The plastic pituitary. J Clin Invest 2003; 112: 1603-1618
    CrossrefPubMedGoogle Scholar
  • 24 Felix I, Asa SL, Kovacs K. et al. Changes in hormone production of a recurrent silent corticotroph adenoma of the pituitary: A histologic, immunohistochemical, ultrastructural, and tissue culture study. Hum Pathol 1991; 22: 719-721
    CrossrefPubMedGoogle Scholar
  • 25 Cooper ME, Murray RM, Kalnins R. et al. The development of Cushing's syndrome from a previously silent pituitary tumour. Aust NZ J Med 1987; 17: 249-251
    CrossrefPubMedGoogle Scholar
  • 26 Brown RL, Muzzafar T, Wollman R. et al. A pituitary carcinoma secreting TSH and prolactin: A non-secreting adenoma gone awry. Eur J Endocrinol 2006; 154: 639-643
    CrossrefPubMedGoogle Scholar
  • 27 Mindermann T, Kovacs K, Wilson CB. Changes in the immunophenotype of recurrent pituitary adenomas. Neurosurgery 1994; 35: 39-44
    CrossrefPubMedGoogle Scholar
  • 28 Dickstein G, Spindel A, Shechner C. et al. Spontaneous remission in Cushingʼs disease. Arch Intern Med 1991; 151: 185-189
    CrossrefPubMedGoogle Scholar
  • 29 Mathioudakis N, Pendleton C, Quinones-Hinojosa A. et al. ACTH-secreting pituitary adenomas: Size does not correlate with hormonal activity. Pituitary 2012; 15: 526-532
    CrossrefPubMedGoogle Scholar
  • 30 Meinardi JR, Wolffenbuttel BH, Dullaart RP. Cyclic Cushingʼs syndrome: A clinical challenge. Eur J Endocrinol 2007; 157: 245-254
    CrossrefPubMedGoogle Scholar
  • 31 Cuevas-Ramos D, Carmichael JD, Cooper O. et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab 2015; 100: 122-131
    CrossrefPubMedGoogle Scholar
  • 32 Drummond J, Roncaroli F, Grossman AB. et al. Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab 2019; 104: 2473-2489
    CrossrefPubMedGoogle Scholar
  • 33 Cooper O. Silent corticotroph adenomas. Pituitary 2015; 18: 225-231
    CrossrefPubMedGoogle Scholar
  • 34 Ben-Shlomo A, Cooper O. Silent corticotroph adenomas. Pituitary 2018; 21: 183-193
    CrossrefPubMedGoogle Scholar
  • 35 Ohta S, Nishizawa S, Oki Y. et al. Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotrophpituitary adenoma of subtype I–immunohistochemical study. Pituitary 2002; 5: 221-223
    CrossrefPubMedGoogle Scholar
  • 36 Hook V, Funkelstein L, Toneff T. et al. Human pituitary contains dual cathepsin L and prohormone convertase processing pathway components involved in converting POMC into the peptide hormones ACTH, alpha-MSH, and beta-endorphin. Endocrine 2009; 35: 429-437
    CrossrefPubMedGoogle Scholar
  • 37 Kojima Y, Suzuki S, Yamamura K. et al. Comparison of ACTH secretion in Cushingʼs adenoma and clinically silent corticotroph adenoma by cell immunoblot assay. Endocr J 2002; 49: 285-292
    CrossrefPubMedGoogle Scholar
  • 38 Matsuno A, Okazaki R, Oki Y. et al. Secretion of high-molecular-weight adrenocorticotropic hormone from a pituitary adenoma in a patient without Cushing stigmata. Case report. J Neurosurg 2004; 101: 874-877
    PubMedGoogle Scholar
  • 39 Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: The silent tumors. Best Pract Res Clin Endocrinol Metab 2012; 26: 447-460
    CrossrefPubMedGoogle Scholar
  • 40 Kho SA, Nieman LK, Gelato MC. Cushing's disease after surgical resection and radiation therapy for nonfunctioning pituitaryadenoma. Endocr Pract 2002; 8: 292-295
    CrossrefPubMedGoogle Scholar
  • 41 Budan RM, Georgescu CE. Multiple pituitary adenomas: A systematic review. Front Endocrinol (Lausanne) 2016; 17: 1
    PubMedGoogle Scholar
  • 42 Tordjman KM, Greenman Y, Ram Z. et al. Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: A Possible Stem Cell Phenomenon. Endocr Pathol 2019; 30: 74-80
    CrossrefPubMedGoogle Scholar
  • 43 Ghervan CM, Nemes C, Florian SI. et al. Silent corticotroph adenoma transformed in secreting adenoma with severe Cushingʼs disease after two pituitary surgeries. Acta Endo (Buc) 2014; 10: 283-292
    PubMed
  • 44 Gogel EL, Salber PR, Tyrrell JB. et al. Cushingʼs disease in a patient with a 'non-functioning' pituitary tumor. Spontaneous developmentand remission. Arch Intern Med 1983; 143: 1040-1042
    CrossrefPubMedGoogle Scholar
  • 45 Nishioka H, Hirano A, Haraoka J. et al. Histological changes in the pituitary gland and adenomas following radiotherapy. Neuropathology 2002; 22: 19-25
    CrossrefPubMedGoogle Scholar
  • 46 Yokoyama S, Kawahara Y, Sano T. et al. A case of non-functioning pituitary adenoma with Cushingʼs syndrome upon recurrence. Neuropathology 2001; 21: 288-293
    CrossrefPubMedGoogle Scholar
  • 47 Sano T, Kovacs K, Asa SL. et al. Pituitary adenoma with “honeycomb Golgi” appearance showing a phenotypic change at recurrence from clinically nonfunctioning to typical Cushing disease. Endocr Pathol 2002; 13: 125-130
    CrossrefPubMedGoogle Scholar
  • 48 Thawani JP, Bailey RL, Burns CM. et al. Change in the immunophenotype of a somatotroph adenoma resulting in gigantism. Surg Neurol Int 2014; 5: 149
    CrossrefPubMedGoogle Scholar
  • 49 Melcescu E, Gannon AW, Parent AD. et al. Silent or subclinical corticotroph pituitary macroadenoma transforming into Cushing Disease: 11-Year Follow-up. Neurosurgery 2013; 72: E144-E146
    CrossrefPubMedGoogle Scholar
  • 50 Ishibashi M, Shimada K, Abe K. et al. Spontaneous remission in Cushing's disease. Arch Intern Med 1993; 153: 251-255
    CrossrefPubMedGoogle Scholar
  • 51 Ikeda H, Yoshimoto T, Kovacs K. et al. Cushing's disease due to female gonadotroph adenoma of the pituitary. Clin Endocrinol (Oxf) 1995; 43: 383-386
    CrossrefPubMedGoogle Scholar